There is considerable interest in the pharmaceutical industry toward development of
antibody-based biotherapeutics because they can selectively bind diverse receptors and …

With increasing numbers of bispecific antibodies (BsAbs) and multispecific products entering
the clinic, recent data highlight immunogenicity as an emerging challenge in the …

In this study, we generated a novel library approach for high throughput de novo
identification of humanized single-domain antibodies following camelid immunization. To …

VHH, ie, VH domains of camelid single-chain antibodies, are very promising therapeutic
agents due to their significant physicochemical advantages compared to classical …

Bispecific antibodies, including bispecific IgG, are emerging as an important new class of
antibody therapeutics. As a result, we, as well as others, have developed engineering …

Cytokines [1–3] are potent immunoregulatory proteins that have proven to be of relevance
as therapeutic modalities. In this regard, cytokines have been approved for the treatment of a …

The development of bispecific antibodies that bind at least two different targets relies on
bringing together multiple binding domains with different binding properties and biophysical …

The surge in the clinical use of therapeutic antibodies has reshaped the landscape of
pharmaceutical therapy for many diseases, including rare and challenging conditions …

Upon reformatting of an antibody to single-chain variable fragment format, a region in the
former variable/constant domain interface of the heavy chain becomes accessible for …

Immunotherapy has emerged as a promising strategy for cancer treatment, with bispecific
antibodies (BsAbs) demonstrating significant therapeutic potential. BsAbs are biological …